mad_scientist
Bluelighter
- Joined
- Apr 20, 2006
- Messages
- 619
tobala said:I believe there are therapies on the horizon, some of which may involve ibogaine, that attempt to "trick" the brain into thinking that there were never dopamine surpluses in the first place, so it senses the dopamine deficit and reverse-neuroadaptation takes place much faster.
Yeah the ibogaine derivative 18-methoxycoronaridine was in phase 2 clinical trials as an anti-addictive drug in humans a while back, been no news on it for some time though. Developed by a Dr Stanley Glick in the US somewhere.
The mechanism is selective antagonist action at alpha3 beta4 nicotinic acetylcholine receptors, and some of his other work demonstrated that any alpha3 beta4 antagonists can exert the same type of anti-addictive effects (he tested ibogaine, 18MC, dextromethorphan, mecamylamine and bupropion, all of which block alpha3 beta4 receptors to some extent). The effects of coadministration were synergistic, so i don't see why a combination product of dextromethorphan, mecamylamine and bupropion shouldn't have similar anti-addictive potential.
A similar mechanism is found in the new anti-smoking drug varenicline, which is an alpha4 beta2 partial agonist and alpha3 beta4 antagonist. Nicotinic pathways seem quite key to the establishment of physical changes in the brain that underlie addiction, so using the same pathways to reverse the changes is a sensible approach.